PET radiopharmaceuticals in Europe: Current use and data relevant for the formulation of summaries of product characteristics (SPCs)

This publication has 28 references indexed in Scilit:

• Estimation of Local Cerebral Glucose Utilization by Positron Emission Tomography: Comparison of [¹⁸F]2-Fluoro-2-Deoxy-D-Glucose and [¹⁸F]2-Fluoro-2-Deoxy-D-Mannose in Patients with Focal Brain Lesions
  Journal of Cerebral Blood Flow & Metabolism, 1991
• Labelled agents for PET studies of the dopaminergic system—some quality assurance methods, experience and issues
  International Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, 1990
• Remote, semiautomated production of 6-[18F]fluoro-l-dopa for human studies with PET
  Applied Radiation and Isotopes, 1989
• Spezielle Probleme des Strahlenschutzes
  Published by Springer Nature ,1988
• Current methodology for oxygen-15 production for clinical use
  Applied Radiation and Isotopes, 1987
• Short-term Studies with the Cryptating Agent Hexaoxa-diaza-bicyclo-hexacosane in Rats
  Published by Springer Nature ,1984
• Design of Steady-State Positron Emission Tomography Protocols for Neurobehavioral Studies
  Journal of Computer Assisted Tomography, 1983
• Effect of a diaza-polyoxa-macrobicyclic complexing agent on the urinary elimination of lead in lead-poisoned rats
  Toxicology and Applied Pharmacology, 1977
• Distribution of a cryptating agent in excreta and its influence on urinary elimination of Na, K, Mg, Ca and Zn in the rat
  Life Sciences, 1975
• Selective 6-hydroxy-DOPA induced degeneration of central and peripheral noradrenaline neurons
  Brain Research, 1972